Therapeutic | Vonlerolizumab |
Target | TNFRSF4 |
Heavy Chain | EVQLVQSGAEVKKPGASVKVSCKASGYTFTDSYMSWVRQAPGQGLEWIGDMYPDNGDSSYNQKFRERVTITRDTSTSTAYLELSSLRSEDTAVYYCVLAPRWYFSVWGQGTLVTVSS |
Light Chain | DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPKLLIYYTSRLRSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGHTLPPTFGQGTKVEIK |
100% seqID Fv Structure | 6ogx [Fvs: CD], 6okn [Fvs: AB, CB] |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
100% seqID Structure | 6okn [Fvs: AB, CB] |
100% seqID Structure | 6ogx [Fvs: CD] |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G1 |
Highest Clinical Trial (June '19) | Phase-II |
Estimated Status (June '19) | Discontinued |
Recorded Developmental Technology | na |
INN Year Proposed | 2015 |
INN Year Recommended | 2017 |
Companies Involved | Genentech |
Conditions Approved | na |
Conditions Active | na |
Conditions Discontinued | Solid tumours, Urogenital cancer |
Notes | Vonlerolizumab and Pogalizumab are the same mAb |